The antiviral drug tecovirimat did not reduce the duration of mpox lesions among children and adults with clade I mpox in the Democratic Republic of the Congo (DRC), based on an initial analysis of data from a randomized, placebo-controlled trial.
Tecovirimat shows no significant impact on mpox lesion duration in DRC study
- Post author:
- Post published:August 18, 2024
- Post category:uncategorized